Home > Insider Trading > Filing (0001209191-14-071519)

Filing Details

Accession Number:: 0001209191-14-071519
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-11-26 16:15:34
Reporting Period:: 2014-11-24

Filing Date:: 2014-11-26
Accepted Time:: 2014-11-26 16:15:34
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1367644	Emergent Biosolutions Inc.	EBS	Pharmaceutical Preparations (2834)	141902018

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1380185	Fuad El-Hibri	2273 Research Blvd., Suite 400 Rockville MD 20850	Chairman	Yes	Yes	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2014-11-24	6,388	$25.00	7,261	No	4	S	Indirect	By Faiza El-Hibri Trust
Common Stock	Disposition	2014-11-24	500	$25.00	13,597	No	4	S	Indirect	By Yusra El-Hibri Trust
Common Stock	Disposition	2014-11-25	2,126	$25.00	5,135	No	4	S	Indirect	By Faiza El-Hibri Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Faiza El-Hibri Trust
No	4	S	Indirect	By Yusra El-Hibri Trust
No	4	S	Indirect	By Faiza El-Hibri Trust

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	2,069,243	Direct
Common Stock	2,350,331	Indirect	By Intervac, L.L.C.
Common Stock	15,845	Indirect	By Karim El-Hibri Trust
Common Stock	1,524,155	Indirect	By Biovac, L.L.C.

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2014.
These shares are held in a trust for the benefit of a child of the reporting person. The reporting person is trustee of this trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Mr. El-Hibri's direct holdings include restricted stock units granted under the 2nd Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan and the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan. Mr. El-Hibri's restricted stock units vest in equal annual installments beginning on the anniversary of the grant date, assuming continued service with the company. Each restricted stock unit represents the right of the reporting person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
Mr. El-Hibri's holdings through Intervac, L.L.C include 1,638,403 shares of common stock held by Mr. El-Hibri and his wife, as tenants by the entirety, through their 37.7% equity interest in Intervac, L.L.C.; 127,721 shares held by Mr. El-Hibri's wife; and 584,207 shares held by trusts indirectly controlled by Mr. El-Hibri or his wife. Mr. El-Hibri disclaims beneficial ownership, for purposes of Section 16 of the Exchange Act or otherwise, of those shares held solely by his wife and those shares held by the trusts.
Mr. El-Hibri holds individually and with his wife, as tenants by the entirety, an aggregate 89.2% equity interest in Biovac, L.L.C. Biovac, L.L.C. is the direct owner of 1,524,155 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of the shares of Common Stock directly owned by Biovac, L.L.C. for purposes of Section 16, except to the extent of his pecuniary interest in 1,359,546 shares.